Valuation : NEOVACS

Market Cap 4.09K 4.75K 3.85K 3.51K 6.56K 449K 6.58K 45.6K 17.61K 230K 17.85K 17.45K 732K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -234K -189K -173K -323K -22.08M -324K -2.24M -866K -11.32M -877K -858K -35.99M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 week-6.66%
Current month-7.50%
1 month-45.59%
3 months-81.50%
6 months-96.64%
Current year-99.57%
1 week 0.31
Extreme 0.31
0.4
1 month 0.31
Extreme 0.31
1.43
Current year 0.31
Extreme 0.31
267
1 year 0.31
Extreme 0.31
5,890
3 years 0.31
Extreme 0.31
32,000,000
5 years 0.31
Extreme 0.31
351,920,000
10 years 0.31
Extreme 0.31
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2020-09-30
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 2003-05-27
Director/Board Member - 2020-04-30
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
2/27/21 Sell

Chief Executive Officer

2,505,144 1.3796%
2/23/21 Sell

Chief Executive Officer

6,391,053 3.5196%
2/23/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.66%-99.99%-100.00% 68.39K
-1.16%-3.97%-2.91%+13.00% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
-0.96%-2.31%+15.75%+45.41% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.54%-1.05%+12.16%+29.80% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.89%-0.23%+54.27%+86.36% 27.5B
Weighted average by Cap. -1.00%+0.05%+88.96%+128.42%

Financials

2023 2024
Net sales 533K 620K 502K 458K 856K 58.59M 859K 5.95M 2.3M 30.04M 2.33M 2.28M 95.52M 434K 505K 408K 372K 697K 47.66M 699K 4.84M 1.87M 24.44M 1.89M 1.85M 77.71M
Net income -8.74M -10.17M -8.22M -7.5M -14.04M -960M -14.08M -97.52M -37.65M -492M -38.17M -37.32M -1.57B -32.91M -38.27M -30.96M -28.25M -52.84M -3.62B -53M -367M -142M -1.85B -144M -141M -5.89B
Net Debt -237K -275K -222K -203K -380K -25.98M -381K -2.64M -1.02M -13.32M -1.03M -1.01M -42.35M -205K -238K -193K -176K -329K -22.53M -330K -2.29M -883K -11.55M -895K -875K -36.72M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
26-09-07 €0.3700 0.00% 9,129
26-09-04 €0.3700 +12.12% 23,957
26-09-03 €0.3300 -4.62% 58,137
26-09-02 €0.3460 -3.89% 49,635
26-09-01 €0.3600 -10.00% 42,132
  1. Stock Market
  2. Stocks
  3. ALNEV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!